SynuSight BioTech
SynuSight BioTech is a Shanghai-based clinical-stage biotech developing α-synuclein PET tracers and seed amplification assays for early differential diagnosis of Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies, using a structure-driven drug design platform.
- Company typePrivate
- Founded2025
- HeadquartersShanghai, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SynuSight BioTech does
SynuSight BioTech (思努赛生物) is a Shanghai-based, clinical-stage biotechnology company developing diagnostic solutions for neurodegenerative diseases, with a focus on synucleinopathies including Parkinson's disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB). The company is incubated under Mabwell (IncuBio) and operates from the Chinese Academy of Sciences Shanghai Institute of Organic Chemistry, Bio-IT Core. SynuSight serves neurological disease diagnosis and clinical research customers — specifically healthcare providers and patients requiring early and accurate differential diagnosis of neurodegenerative conditions, and pharmaceutical companies and research institutions that need specific biomarkers to stratify patients and monitor treatment efficacy.
The company operates a Structure-Driven Drug Design platform that integrates cryo-EM electron diffraction, helical filament imaging, in-cell NMR spectroscopy, AI algorithms, and computer-aided drug design (CADD) to enable de novo development of next-generation tracers with novel molecular scaffolds. Its lead asset SST001/18F-FD4 is an α-synuclein-targeted PET tracer that has received FDA IND clearance and NMPA Phase I clinical trial approval, with investigator-initiated trials demonstrating excellent blood-brain barrier penetration and superior imaging performance in PD and MSA patients. The pipeline includes SST002 (PET tracer, early discovery) and two biomarker candidates (SSA001 and SSA002). In May 2026, the company published the TPPP/p25 seed amplification assay (TPPP/p25-SAA) in Cell — a cerebrospinal fluid-based diagnostic that specifically identifies pathological TPPP/p25 seeds to distinguish MSA from PD, DLB, and healthy controls.
SynuSight is pre-revenue. Its commercial model is built around regulatory-approved diagnostic tracer sales post-approval, complemented by biomarker licensing and potential companion diagnostic partnerships with pharmaceutical companies. The go-to-market motion is sales-led through clinical validation partnerships with major research hospitals (Huashan/Fudan, Jiangnan) and foundation grant funding (notably a US$3.84 million grant from The Michael J. Fox Foundation). Pricing is not publicly disclosed, and products are not yet commercialized. Geographic focus spans China and the United States, positioning the company for dual-jurisdiction clinical development and future global licensing opportunities.
SynuSight BioTech firmographics
Firmographics- Name
- SynuSight BioTech
- Legal name
- SynuSight BioTech
- Website
- https://synusight.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SynuSight BioTech is a Shanghai-based clinical-stage biotech developing α-synuclein PET tracers and seed amplification assays for early differential diagnosis of Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies, using a structure-driven drug design platform.
- Ownership category
- akta.pro rank
SynuSight BioTech industry classification
Industry- Product category
- Neurodegenerative Disease Diagnostics (PET Imaging Tracers and Biomarkers)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where SynuSight BioTech is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
SynuSight BioTech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Diagnostic Tracer Commercialization: Pre-revenue clinical-stage company developing PET tracers for neurodegenerative disease diagnosis. Revenue expected from diagnostic imaging agent sales upon regulatory approval.
- Biomarker Development: Novel biomarker candidates (SSA001, SSA002) in pipeline for diagnostic applications, potential companion diagnostics partnerships with pharmaceutical companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
SynuSight BioTech product offering
Product offeringCore offering
SynuSight BioTech develops α-synuclein-targeted PET imaging tracers and cerebrospinal fluid biomarkers for the early and differential diagnosis of neurodegenerative synucleinopathies, including Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Its lead product SST001/18F-FD4 is in Phase I clinical trials in both China (NMPA-approved) and the United States (FDA IND-cleared), supported by a US$3.84 million grant from The Michael J. Fox Foundation. The company also offers a first-in-class TPPP/p25 seed amplification assay and a pipeline of biomarkers (SSA001, SSA002) and a second PET tracer (SST002).
Product overview
SynuSight BioTech is a biotechnology company developing diagnostic solutions for neurodegenerative diseases. The company operates a structure-driven drug design platform and offers a portfolio of α-synuclein-targeted PET tracers and novel biomarkers. The core product SST001/18F-FD4 is an α-Syn PET tracer for Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy bodies, currently in Phase I clinical trials in both China and the US. The pipeline also includes SST002 (PET tracer) and SSA001/SSA002 (novel biomarkers), all in early discovery stages. Additional offerings include the TPPP/p25 seed amplification assay for diagnosing synucleinopathies.
Differentiator
Problem solved
Functional benefit
Products and services
- SST001/18F-FD4 (α-Syn PET Tracer) α-Synuclein-targeted PET imaging tracer for early diagnosis of Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Developed through SynuSight's Structure-Driven Drug Design platform combining systematic studies of ligand-α-Syn interactions with AI and CADD approaches. Demonstrates excellent blood-brain barrier penetration and superior imaging performance in investigator-initiated clinical trials. For neurology departments, nuclear medicine physicians, and clinical research hospitals.
- SST002 (PET Tracer) Second PET tracer candidate in SynuSight's pipeline at the early discovery stage, with an undisclosed indication. Represents the platform's expansion beyond α-synuclein imaging into additional neurodegenerative disease targets.
- SSA001 (Novel Biomarker) Novel biomarker candidate in early discovery stage with undisclosed indication, positioned for neurodegenerative disease diagnostic applications and potential companion diagnostics partnerships with pharmaceutical companies.
- SSA002 (Novel Biomarker) Novel biomarker candidate in early discovery stage with undisclosed indication, intended for neurodegenerative disease diagnostic applications.
- TPPP/p25 Seed Amplification Assay (TPPP/p25-SAA) First-in-class cerebrospinal fluid detection method that specifically identifies pathological TPPP/p25 seeds to diagnose Multiple System Atrophy and distinguish it from Parkinson's disease, Dementia with Lewy Bodies, and healthy controls. Developed through a collaboration with Shanghai Jiao Tong University's Bio-X Institute, the Chinese Academy of Sciences, and Huashan Hospital (Fudan University), published in Cell. For neurology research and differential diagnosis of synucleinopathies.
Quantifiable outcome
- 18F-FD4 demonstrated excellent blood-brain barrier penetration and superior imaging performance in PD and MSA patients in early IIT trials
- +3 more outcomes
Companies that use SynuSight BioTech
Customer profileSegments2 records
Ideal customer profiles2 records
SynuSight BioTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SynuSight BioTech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Shanghai Jiao Tong University - Bio-X InstitutecoreCollaborative study published in Cell developing the TPPP/p25 seed amplification assay for diagnostic classification of synucleinopathies. Researchers from the Bio-X Institute contributed to advancing diagnostic capabilities for Multiple System Atrophy and other neurodegenerative diseases.
- Chinese Academy of SciencescoreResearch collaboration with Chinese Academy of Sciences teams on the Cell-published study for TPPP/p25-SAA development and neurodegenerative disease diagnostics.
- Huashan Hospital, Fudan UniversitycoreClinical trial site for SST001 Phase I study evaluating safety, tolerability, and pharmacokinetics. Also contributed research teams to the TPPP/p25-SAA collaboration published in Cell.
- Affiliated Hospital of Jiangnan UniversitycoreClinical trial site for SST001 Phase I clinical trial, enrolling healthy volunteers and patients to evaluate safety, tolerability, and pharmacokinetics of the α-syn PET tracer.
- Mabwell (IncuBio)coreSynuSight Biotech is Mabwell's incubated company, developed under Mabwell's therapeutic innovation ecosystem. Mabwell provided corporate backing and incubation support for the biotech's formation and development.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
SynuSight BioTech competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly (Avid Radiopharmaceuticals): Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly, pioneered approved amyloid PET tracers (Amyvid) and tau PET tracers (Tauvid). It represents a broad incumbent in neurodegenerative PET imaging and a potential strategic acquirer of SynuSight's α-Syn program.
- Biogen: Biogen is a major neurodegenerative therapeutics company (Leqembi, Aduhelm) that has invested in companion diagnostics and is a likely partner or acquirer for α-Syn PET assets. It represents a broad incumbent with strategic interest in SynuSight's diagnostic capabilities.
- GE HealthCare: GE HealthCare has built a major radiopharmaceutical and PET imaging portfolio (including its acquisition of MIM Software and ongoing investment in neurology tracers). It is a broad incumbent in molecular imaging and a likely strategic acquirer or commercial partner for SynuSight.
- Eisai: Eisai develops both AD therapeutics (Leqembi) and associated PET diagnostic agents. It is a broad incumbent in neurodegeneration combining diagnostics and therapy, paralleling SynuSight's dual diagnostic/therapeutic strategy.
Direct peers
- AC Immune: AC Immune is a Swiss-listed biotech developing both therapeutics and diagnostics (PET tracers) targeting α-synuclein and tau for neurodegenerative diseases. It directly competes with SynuSight in α-synuclein-targeted diagnostics and pursues similar FIC/BIC positioning.
- Life Molecular Imaging: Life Molecular Imaging is a radiopharmaceutical company focused on PET imaging agents for neurodegenerative diseases, including amyloid and tau tracers. It is a direct peer to SynuSight in CNS PET tracer development and commercialization.
- Amprion: Amprion is a pioneer in seed amplification assays (SAA) for synucleinopathies, directly competing with SynuSight's TPPP/p25-SAA technology for diagnosis of PD, MSA, and DLB. Both companies target the same unmet need of differential diagnosis of synucleinopathies using protein-misfolding detection.
- Cerveau Technologies: Cerveau develops and licenses tau PET imaging ligands (e.g., MK-6240, flortaucipir successor programs) for Alzheimer's disease and related neurodegenerative disorders. It is a direct peer in CNS-targeted PET radiopharmaceuticals, addressing similar clinical and pharma-partner demand for neuroimaging tools.
Emerging players
- C2N Diagnostics: C2N Diagnostics commercializes PrecivityAD, a blood-based biomarker test for Alzheimer's disease pathology. As an emerging neurodegenerative diagnostics player with biomarker expertise, it represents a comparable business model and clinical positioning to SynuSight's biomarker pipeline.
Others
- Quanterix: Quanterix provides ultra-sensitive biomarker detection platforms (Simoa) widely used in neurodegeneration research and clinical trials. It is an enabling/adjacent peer — not a direct competitor, but its platform supports similar biomarker-based diagnostic development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SynuSight BioTech social profiles
Digital presenceSynuSight BioTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynuSight BioTech leadership team
Management profileNumber of profiles
Profiles6 records
SynuSight BioTech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynuSight BioTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynuSight BioTech
What does SynuSight BioTech do?
SynuSight BioTech develops α-synuclein-targeted PET imaging tracers and cerebrospinal fluid biomarkers for the early and differential diagnosis of neurodegenerative synucleinopathies, including Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Its lead product SST001/18F-FD4 is in Phase I clinical trials in both China (NMPA-approved) and the United States (FDA IND-cleared), supported by a US$3.84 million grant from The Michael J. Fox Foundation. The company also offers a first-in-class TPPP/p25 seed amplification assay and a pipeline of biomarkers (SSA001, SSA002) and a second PET tracer (SST002).
Is SynuSight BioTech a public or private company?
SynuSight BioTech is a private company. It is classified as corporate owned and is currently operating.
When was SynuSight BioTech founded?
SynuSight BioTech was founded in 2025. It employs 1 to 10 people.
Where is SynuSight BioTech based?
SynuSight BioTech is headquartered in Shanghai, China, in the Asia region.
How does SynuSight BioTech make money?
Two revenue lines are on record. Diagnostic Tracer Commercialization is the primary driver. The others are biomarker Development.
Who are SynuSight BioTech's main competitors?
Broad incumbents on record are Eli Lilly (Avid Radiopharmaceuticals), Biogen, GE HealthCare and Eisai. Direct peers are AC Immune, Life Molecular Imaging, Amprion and Cerveau Technologies. C2N Diagnostics is listed as an emerging player. Quanterix is listed as an others.
Does SynuSight BioTech have an API?
No public API is recorded for SynuSight BioTech.
What industry is SynuSight BioTech in?
SynuSight BioTech's product category is Neurodegenerative Disease Diagnostics (PET Imaging Tracers and Biomarkers). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2835.